Vera Therapeutics, Inc.
VERA
$39.96
-$1.21-2.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -109.78% | -72.18% | -127.04% | -82.13% | -69.27% |
| Total Depreciation and Amortization | 145.45% | 437.50% | 693.33% | 672.73% | 1,275.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 115.74% | 147.98% | 197.51% | 110.09% | 90.40% |
| Change in Net Operating Assets | 1,523.35% | 48.15% | 117.81% | -9.50% | 64.92% |
| Cash from Operations | -78.64% | -67.84% | -121.12% | -60.82% | -55.83% |
| Capital Expenditure | 84.19% | 44.12% | -133.71% | -- | -923.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 136.59% | 81.28% | 227.29% | 107.07% | -1,285.55% |
| Cash from Investing | 136.44% | 82.06% | 225.87% | 106.98% | -1,293.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -12.42% | 5.98% | -86.51% | -99.48% | 399,108.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 16.16% | -- | -- | -- | -- |
| Cash from Financing | -12.17% | 7.85% | 489.85% | -99.45% | 1,212.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 354.12% | 298.53% | 86.44% | -260.33% | 258.50% |